FDA approvals: Tregzi leads 8 actions

From June 26 at 5:28 p.m. through July 3 at 5:00 p.m. ET, the FDA approval window produced eight qualifying actions: one novel biologics license application (BLA), three drug label expansions, and four device 510(k) clearances. 1 2 3 4 5 6 7 8 The center of gravity was cell and gene therapy: Orca Bio moved Tregzi into commercial launch, and Vertex expanded CASGEVY to children as young as age 2. 9 4

Tregzi is the week's lead commercial story because it changes more than a label. FDA approved the Orca Bio therapy for hematologic and immune reconstitution and improved chronic graft-versus-host-disease-free survival in adults with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or mixed phenotype acute leukemia receiving matched-donor allogeneic HSCT. 1 The product received priority review, orphan drug designation, and regenerative medicine advanced therapy (RMAT) designation, which is FDA's expedited pathway for regenerative therapies that may address serious diseases. 1

The previous regulatory state was no approved precision-engineered Treg graft for this transplant setting. The new state is a three-component live-cell product: hematopoietic stem and progenitor cells and regulatory T cells are infused on Day 0, followed by conventional T cells on Day +2 to Day +3. 1 The clinical logic is to separate immune reconstitution from graft-versus-host-disease control, while using tacrolimus alone for GVHD prophylaxis. 1

The efficacy signal is large but should be read inside a transplant-specific context. In Precision-T, a 187-patient multicenter open-label randomized Phase 3 trial, 12-month chronic GVHD-free survival was 78% with Tregzi plus tacrolimus versus 38% with standard allogeneic HSCT plus tacrolimus and methotrexate; the hazard ratio was 0.26 with a 95% confidence interval of 0.14 to 0.47. 1 Moderate-to-severe chronic GVHD at 12 months was 12.6% with Tregzi versus 44.0% in the control group, while overall survival was 94% versus 83%. 11

Safety remains transplant-grade. FDA and Orca Bio list warnings for graft failure, acute and chronic GVHD, infusion reactions, secondary and donor-derived malignancies, and transmission of infectious agents; common adverse reactions reported at 20% or more included mucositis, diarrhea, rash, viral infection, abdominal pain, vomiting, nausea, bacterial infection, bleeding, acute GVHD, edema, and fungal infection. 1 11

The commercial read is direct: Tregzi enters at a wholesale acquisition cost of $428,000 for a one-time therapy, and Orca Bio plans an initial launch through a small number of treatment centers before reaching about 25 centers by year-end 2026. 9 The constraint is the operating model. Orca Bio says Tregzi has a 72-hour vein-to-vein manufacturing window, uses a 100,000-square-foot Sacramento facility, and has added an East Coast manufacturing footprint in Princeton, New Jersey. 9 12 For investors, center activation and manufacturing reliability are the early launch metrics to watch.

Zoryve's label now reaches children as young as age 2 with plaque psoriasis, including intertriginous areas, after previously covering patients age 6 and older. 2 That change matters because topical corticosteroids have long-term and sensitive-area limitations in young children, while Zoryve is a once-daily phosphodiesterase-4 (PDE4) inhibitor without steroid, polyethylene glycol, propylene glycol, ethanol, fragrance, or duration-of-use restrictions in the company-described label materials. 2

The supporting pediatric dataset is small but targeted. The 4-week MUSE pharmacokinetic study in children age 2 to 5 enrolled 10 patients, and HCPLive reported 90% Investigator Global Assessment success, 90% PASI-75, and 90% Worst Itch Numeric Rating Scale success at Week 4 in that cohort. 13 Arcutis also cites a 24-week open-label extension and safety and efficacy consistency with adult and adolescent DERMIS Phase 3 studies. 2

For clinicians, the practical change is first-line topical choice in a very young group. For Arcutis, the label supports the Zoryve franchise rather than creating a separate market; the company says this is Zoryve's seventh FDA approval in four years and that Zoryve is the top prescribed branded topical across atopic dermatitis, seborrheic dermatitis, and plaque psoriasis combined. 2

Skyrizi moved from an adult immune-mediated disease growth engine into pediatric psoriatic disease. FDA approved risankizumab-rzaa for children age 6 and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, and for children age 6 and older with active psoriatic arthritis. 3 The approval also adds weight-based dosing: a new 55-mg prefilled syringe for patients under 40 kg and the existing 150-mg syringe or pen for patients at or above 40 kg. 3

The evidence base is larger than Zoryve's youngest-child dataset because Skyrizi's psoriasis label relies on the Phase 3 OptIMMize program. AbbVie reported that 69% of patients achieved static Physician's Global Assessment clear or almost clear skin at Week 16, 85% achieved PASI-75 at Week 16, and 95% of early responders who continued treatment maintained response at Week 52 versus 39% of those who stopped. 3 Pediatric psoriatic arthritis approval was supported through pharmacokinetic modeling and extrapolation from controlled adult PsA studies. 3

The commercial effect is incremental for AbbVie but important for prescribing standards. Skyrizi generated $4.48 billion in first-quarter 2026 revenue, up 31% operationally year over year, and AbbVie has positioned Skyrizi and Rinvoq as its main post-Humira growth pair. 14 The pediatric approval gives AbbVie a first IL-23 inhibitor claim in children, while Zoryve serves a different tier: topical management for younger and generally less severe disease. 2 3

CASGEVY's label expansion is the most consequential access event of the week. FDA expanded the CRISPR/Cas9-edited autologous cell therapy to patients age 2 and older with sickle cell disease and recurrent vaso-occlusive crises, or transfusion-dependent beta thalassemia; the therapy had previously been approved for sickle cell disease age 12 and older in December 2023 and transfusion-dependent beta thalassemia age 12 and older in January 2024. 4 10

FDA granted the expansion under the Commissioner's National Priority Voucher pilot program 53 days after filing, which made it the eighth approval under that pilot. 10 The clinical rationale is earlier intervention before cumulative organ damage, but the youngest ages were not supported by completed outcomes in 2- to 4-year-olds. Vertex and FDA state that the 2-and-older indication used clinical data, product characteristics, and extrapolation, while the 5- to under-12-year-old cohorts in CLIMB-141 and CLIMB-151 had completed enrollment and dosing. 4 10

The early pediatric efficacy readout was strong in evaluable patients. In the sickle cell disease study, all 8 evaluable patients among 11 enrolled children age 5 to under 12 achieved VF12, meaning no protocol-defined severe vaso-occlusive crises for at least 12 consecutive months within the first 24 months after infusion. 4 In the transfusion-dependent beta thalassemia study, 8 of 9 evaluable patients among 15 enrolled achieved transfusion independence for 12 consecutive months, with a median transfusion-independence duration of 20.1 months. 4

Access is now the harder problem. Vertex says about 5,500 additional US children are eligible and more than 75 authorized treatment centers are activated nationwide. 4 The therapy still requires myeloablative conditioning, and BioSpace reported busulfan conditioning, infertility risk, and an approximately 12-month treatment journey as major adoption barriers. 15 For investors, the signal was immediate: Yahoo Finance reported VRTX up 6% and CRSP up 8% on July 2, with CRISPR Therapeutics receiving a 40% share of CASGEVY net profits under the Vertex collaboration. 16

A 510(k) clearance means FDA found a device substantially equivalent to a legally marketed predicate device; it is not the same regulatory route as a premarket approval (PMA), which is used for higher-risk devices and requires a more direct showing of safety and effectiveness. This week's device actions are therefore best read as workflow and access signals, not as PMA-level clinical validation.

Visby Medical received 510(k) clearance for an over-the-counter at-home multiplex PCR test that detects influenza A, influenza B, and COVID-19 in about 30 minutes. 5 The previous consumer state was dominated by faster but less sensitive antigen testing, while Visby's change is bringing PCR sensitivity into the home setting for three common respiratory viruses. 5

The commercial case is partner-led consumer diagnostics. Visby says the respiratory test is its second over-the-counter PCR product after a 2025 FDA-authorized STI test, and its STI product is sold through partners including DoorDash, Labcorp, Quest Diagnostics, Wisp, Everlywell, and RAINN. 5 Medical Device Network cited GlobalData forecasts of about $263 million for the global influenza testing market and about $4.3 billion for the COVID-19 testing market in 2035. 17

Tenon Medical's updated Catamaran SI Joint Fusion System clearance covers device upgrades and the reclassification of selected instruments from disposable to reusable. 6 The system uses a single titanium implant delivered through a minimally invasive inferior-posterior approach to the sacroiliac joint. 6

This is a cost-structure clearance more than a new clinical category. Tenon says more than 1,500 Catamaran fixation devices have been implanted since US launch in October 2022, and CEO Steven Foster said the reusable-instrument transition should reduce per-procedure cost and support gross margin. 6 Investors should read the next signal in gross margin and cash-flow disclosures, not in the clearance itself.

StarMed America's clearance is notable because the company says it is the first US company with an FDA-cleared thyroid nodule radiofrequency ablation indication. 7 The cleared devices include the Viva Combo RF generator, Star RF electrode, and Viva RF electrode for ultrasound-guided percutaneous ablation of cytologically confirmed benign thyroid nodules in adults who have symptomatic, cosmetic, or autonomous functioning nodules; the autonomous functioning nodule volume must be under 10 mL. 7

The evidence basis is literature-driven rather than a single new trial. StarMed says its submission was supported by a systematic literature review of 42 peer-reviewed publications, each showing at least 50% volume reduction at six months, and that more than 300 global clinical publications have used STARMED devices. 7 For clinicians, the practical effect is cleaner device labeling and an easier value-analysis path for institutions already considering thyroid RFA programs.

Spiro Robotics received 510(k) clearance for Spiro-VISTA, a handheld system that combines video laryngoscopy and steerable endotracheal-tube delivery for adult in-hospital intubation. 8 The prior workflow typically separated visualization from tube steering or required more complex adjunct tools; Spiro's claim is that one clinician can operate the integrated platform across routine and difficult airway cases. 8

The early performance data are promising but small. MedTech World reported more than 130 preclinical and clinical procedures with 100% first-pass success, including a first-in-human study of 30 expected difficult-airway patients with 100% first-pass success and no adverse events, published in Anesthesia & Analgesia in 2026. 8 Spiro plans phased commercial rollout in the second half of 2026 through selected academic medical centers and high-risk hospitals. 8 The next proof point is whether broader use keeps the first-pass and complication profile intact.

For investors, Tregzi and CASGEVY deserve the closest follow-through. Tregzi needs manufacturing reliability, center onboarding, and reimbursement execution to justify a $428,000 launch price. 9 CASGEVY has a larger eligible population after the pediatric expansion, but conditioning burden and treatment duration still limit uptake. 4 15

For clinicians, the immediate workflow changes are specific: transplant centers need Tregzi referral and scheduling protocols; pediatric dermatology gains a topical option down to age 2 and a systemic biologic option from age 6; sickle cell and beta thalassemia teams need earlier gene-therapy counseling for families. 1 2 3 10

For patient advocates, the practical access work is now about navigation. CASGEVY has more than 75 activated US treatment centers, but families still face conditioning, fertility, travel, and time-away-from-care barriers. 4 15 Young psoriasis patients now have more age-appropriate options, but the topical-versus-biologic decision still depends on severity, joint involvement, infection risk, and payer access. 2 3